Search

News Possibilities of Cannabis Use in Tourette Syndrome Therapy

A retrospective analysis and online survey conducted at a psychiatric clinic in Hanover, Germany, investigated the effectiveness and safety of using cannabis products in patients with Tourette syndrome in real-world practice.

Source: Medical Cannabis 20. 6. 2024

News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.

Source: Chronic Heart Failure and Lipidology 23. 12. 2022

News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.

Source: Diabetes 19. 4. 2022

News Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa –⁠ another approved indication for this biological agent

In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS in adults who have not responded adequately to conventional systemic therapy.

Source: Psoriasis 1. 7. 2024

News Long-term Benefit of Luspatercept Therapy –⁠ Fresh Data from the MEDALIST Study

The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia, improve or maintain quality of life, and prolong the time to progression to higher-risk MDS (HR-MDS) or acute myeloid leukemia (AML). To manage anemia, we can resort to transfusion therapy or administer epoetins, lenalidomide, or luspatercept, the first representative of a class of drugs that support erythrocyte maturation. Last year's data from the follow-up of patients enrolled in the MEDALIST study pertain specifically to the latter.

Source: Myelodysplastic Syndrome (MDS) 22. 4. 2024

News The Link Between Various Sleep Disorders and the Onset of Depression: What Findings Did the Population Study in Denmark Bring?

A Danish population study published in June 2019 examined the link between different types of sleep disorders and the risk of developing depression. Which disorders confirmed this link after evaluating data from tens of thousands of patients?

Source: Depression and Anxiety 17. 3. 2020

News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome

A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.

Source: Myelodysplastic Syndrome (MDS) 24. 5. 2024

News Treatment of Motor Symptoms of Parkinson's Disease

Parkinson's disease (PD) is one of the few neurodegenerative disorders for which effective symptomatic treatment is available. Unfortunately, causal or even neuroprotective therapy with proven efficacy does not yet exist, but properly chosen symptomatic therapy can positively influence the motor manifestations of the disease and significantly improve the patient's quality of life.

Source: Parkinson's Disease 12. 5. 2021

News Recent findings on the role and potential of L. reuteri in the therapy of GIT diseases

Probiotics contain bacterial or yeast strains similar to beneficial types naturally occurring in the human gastrointestinal tract. Their role in the therapy of gastrointestinal diseases has been extensively researched, demonstrating significant effects on a number of nosological units. One modality of probiotic therapy involves the administration of the bacteria L. reuteri, specifically the laboratory-modified strain DSM 17938.

Source: GI, colic and microbiome 20. 10. 2022

News Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke

A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.

Source: Pain Management 13. 5. 2024

News Comprehensive View on Care for Patients with Urostomy

Thanks to improvements in surgical techniques and shorter hospital stays, patients with a stoma are returning to their home environment and to the care of outpatient doctors sooner. Quality care in the postoperative period is a crucial element in the prevention of complications, support of healing, and education of ostomy patients. Doctors caring for these patients should approach them comprehensively, considering all their needs and aspects.

Source: Ostomy 28. 2. 2020

News Most Common Dermatoses Around the Stoma

The incidence of stomal complications ranges between 20 and 70%. One type of complication is dermatoses affecting the peristomal skin. These issues can occur in the early postoperative period, but also several years later.

Source: Ostomy 4. 5. 2020

News Importance of pH in Care for Stoma Patients

Maintaining good quality peristomal skin and preventing complications related to the stoma site are integral parts of comprehensive care for patients with stomas. The pH of the skin also plays an important role in this issue, as it can significantly affect the condition of the skin, the development of complications, the quality of life of patients, and consequently impact the economic aspect of stoma care.

Source: Ostomy 19. 3. 2020

News How Does Erdosteine Perform in Combination with Antibiotics?

Erdosteine is an oral mucoactive drug that reduces mucus viscosity by degrading disulfide bonds in the mucin polymer. It achieves this effect through a free thiol group in its main active metabolite, N-thiodiglycolyl-homocysteine. In addition to its mucolytic action, erdosteine exhibits antioxidant and anti-inflammatory effects and reduces bacterial adhesion, thereby enhancing the effectiveness of certain antibiotics. We provide a summary of study results demonstrating its effect on enhancing the efficacy of drugs administered in the treatment of respiratory diseases.

Source: Cough Therapy 1. 11. 2022

News Is Baricitinib Suitable for Long-Term Treatment of Rheumatoid Arthritis?

The nature of rheumatoid arthritis requires effective and long-term treatment. The current analysis of data from the long-term extension RA-BEYOND reveals the potential of baricitinib in maintaining low disease activity and remission with long-term use.

Source: Biological Treatment 12. 3. 2021